Follistatin 344

Fitness

Also known as: FST-344, Follistatin isoform 344

Limited Evidence

What is Follistatin 344?

A 344-amino acid isoform of follistatin, a naturally occurring glycoprotein that binds and neutralizes myostatin — the protein that limits muscle mass. By inhibiting myostatin, follistatin theoretically removes the body's built-in ceiling on muscle growth. Popularized following myostatin knock-out animal studies, but human evidence for exogenous peptide administration is negligible.

How it works

Follistatin binds myostatin (GDF-8) with high affinity, sequestering it and preventing it from signaling through ActRIIB receptors. Myostatin is a negative regulator of muscle growth — without its inhibitory signal, satellite cells proliferate more freely and hypertrophy is less constrained. The FST-344 isoform has high affinity for heparan sulfate proteoglycans, anchoring it to local tissue rather than circulating systemically.

What marketers claim

  • removes the genetic ceiling on muscle mass
  • produces steroid-like gains without side effects
  • proven in humans based on animal studies
  • safe indefinitely at any dose

What evidence supports

  • gene therapy delivery to macaques produced significant muscle hypertrophy without toxicity (Nationwide Children's Hospital, 2009)
  • pilot gene therapy trial in Becker muscular dystrophy (6 patients) showed modest muscle function improvements
  • myostatin inhibition consistently produces hypertrophy across multiple animal species

Research evidence

Key studies on Follistatin 344, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.

Follistatin gene delivery enhances muscle in nonhuman primates

2009Animal Studyn = 6 macaques

Finding: 15–27% muscle mass increase in treated muscles with no adverse effects at 8-week follow-up; confirms follistatin-mediated myostatin inhibition is effective in primates.

Limitation: Gene therapy in primates is completely different from exogenous synthetic peptide injection; delivery mechanism, duration of expression, and systemic exposure differ fundamentally.

Pilot trial of follistatin gene therapy for Becker muscular dystrophy

2015Clinical Trialn = 6 adults with Becker muscular dystrophy

Finding: Modest but measurable improvements in 6-minute walk test and muscle volume in treated limbs; no serious adverse events at 6-month follow-up.

Limitation: Disease population (BMD) with impaired baseline muscle function; gene therapy delivery mechanism; extremely small sample; results do not generalize to healthy adults seeking hypertrophy.

Best for

experimental recovery protocols under medical supervisionthose interested in experimental muscle growth research

What to expect

Realistic timeline based on available research. Individual results vary.

Human timeline unknown

Gene therapy trials measured outcomes at 8 weeks post-administration. Peptide injection timeline, if any effect exists, is entirely uninvestigated in humans. The FST-344 isoform binds heparan sulfate proteoglycans, suggesting local tissue retention — but this has not been characterized pharmacokinetically for injected peptide.

Safety notes & concerns

Full safety guide →
  • virtually no human evidence for exogenous peptide administration — the gene therapy data involves completely different delivery
  • follistatin also inhibits FSH — chronic suppression could impair reproductive function in both sexes
  • follistatin inhibits activin, which has roles in bone density, glucose metabolism, and tumor suppression
  • large protein peptides extremely difficult to synthesize correctly — commercial purity uncertain
  • long-term systemic myostatin and activin blockade in healthy humans entirely unstudied

Pairs well with

professional medical supervision if genuinely considering use

Use caution with

those trying to conceive (FSH suppression)active cancer — myostatin and activin blockade have potential oncological implicationsanyone not under close medical supervision

Frequently asked questions

What about "super baby" and double-muscled cattle stories — don't they prove myostatin inhibition works?

These cases involve myostatin gene mutations (loss-of-function), not follistatin. The 2004 German infant case (born with extreme muscularity due to myostatin gene defect) and Belgian Blue cattle confirm myostatin's role in limiting muscle growth, but they do not validate exogenous follistatin peptide injections as a safe or effective way to replicate this effect in adults.

Why not take a follistatin supplement pill?

Follistatin is a ~35 kDa glycoprotein — it cannot survive oral digestion intact and would be broken down into individual amino acids before absorption. Many commercial "follistatin supplements" contain egg yolk powder (which naturally contains follistatin), but quantities present are far too small and not bioavailable in peptide form to affect systemic myostatin levels.

Related fitness peptides

🧪

Take the Peptide Quiz

Get personalized recommendations

🔬

Stack Builder

Build a routine with Follistatin 344

Last updated: 2026-06-10

Medical Disclaimer

The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.